CLINICAL LASERTHERMIA SYSTEMS AB Financials Clinical Laserthermia Systems AB
Equities
CLS B
SE0022049920
Advanced Medical Equipment & Technology
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.139 SEK | -2.63% |
|
-5.76% | -77.76% |
| May. 31 | Clinical Laserthermia Systems to Raise SEK59 Million via Rights Issue | MT |
| May. 29 | Clinical Laserthermia Systems AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 249.8 | 215.1 | 210 | 269.5 | 102.2 | 49.52 | 49.52 | - |
| Enterprise Value (EV) 1 | 226.8 | 230.3 | 210 | 269.5 | 123.4 | 169.5 | 19.82 | 46.52 |
| P/E ratio | -9.03 x | -5.17 x | -3.64 x | -3.66 x | -0.96 x | - | - | - |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 31 x | 34.2 x | - | - | 16.3 x | 22.3 x | 1.27 x | 0.74 x |
| EV / Revenue | 28.2 x | 36.6 x | - | - | 19.7 x | 20.5 x | 0.51 x | 0.69 x |
| EV / EBITDA | -6.82 x | -5.81 x | - | - | -1.9 x | -2.68 x | -0.38 x | -1.94 x |
| EV / FCF | -5,518,599 x | -5,913,845 x | - | - | -1,796,419 x | - | -353,999 x | -1,723,108 x |
| FCF Yield | -0% | -0% | - | - | -0% | - | -0% | -0% |
| Price to Book | 5.02 x | 26.7 x | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 173 | 173 | 227 | 329 | 624 | 7,855 | 7,855 | - |
| Reference price 2 | 1,444 | 1,240 | 924.0 | 819.0 | 163.8 | 6.305 | 6.305 | 6.305 |
| Announcement Date | 2/14/19 | 2/28/20 | 2/26/21 | 2/24/22 | 2/23/23 | 2/23/24 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8.051 | 6.291 | - | - | 6.268 | 8.273 | 39 | 67 |
| EBITDA 1 | -33.24 | -39.68 | - | - | -64.99 | -63.22 | -52 | -24 |
| EBIT 1 | -33.45 | -42.36 | - | - | -67.44 | -65.93 | -54 | -29 |
| Operating Margin | -415.49% | -673.33% | - | - | -1,075.97% | -796.97% | -138.46% | -43.28% |
| Earnings before Tax (EBT) 1 | -32.86 | -42.33 | - | - | -71.26 | -80.88 | -54 | -29 |
| Net income 1 | -32.86 | -42.33 | -56.24 | -63.62 | -70.66 | -79.79 | -54 | -29 |
| Net margin | -408.09% | -672.8% | - | - | -1,127.31% | -964.49% | -138.46% | -43.28% |
| EPS | -160.0 | -240.0 | -254.0 | -224.0 | -170.0 | - | - | - |
| Free Cash Flow | -41.1 | -38.95 | - | - | -68.7 | - | -56 | -27 |
| FCF margin | -510.5% | -619.14% | - | - | -1,096.08% | - | -143.59% | -40.3% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/14/19 | 2/28/20 | 2/26/21 | 2/24/22 | 2/23/23 | 2/23/24 | - | - |
1SEK in Million
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.587 | 1.252 | 1.978 | 4.456 | 3.14 | 4.6 | 9.7 | 13.5 |
| EBITDA | -14.5 | - | - | -19.67 | - | - | - | - |
| EBIT 1 | -15.14 | -17.01 | - | -20.41 | -16.99 | -16.5 | -12.9 | -10.1 |
| Operating Margin | -2,579.39% | -1,358.95% | - | -457.99% | -541.15% | -358.7% | -132.99% | -74.81% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 5/25/23 | 8/25/23 | 11/17/23 | 2/23/24 | - | - | - | - |
1SEK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 15.2 | - | - | 21.2 | - | - | - |
| Net Cash position 1 | 23 | - | - | - | - | 14.9 | 29.7 | 3 |
| Leverage (Debt/EBITDA) | - | -0.3841 x | - | - | -0.3269 x | - | - | - |
| Free Cash Flow | -41.1 | -39 | - | - | -68.7 | - | -56 | -27 |
| ROE (net income / shareholders' equity) | -79.4% | -146% | - | - | -456% | - | -104% | -64% |
| ROA (Net income/ Total Assets) | -63.8% | -87.6% | - | - | - | - | - | - |
| Assets 1 | 51.48 | 48.34 | - | - | - | - | - | - |
| Book Value Per Share | 288.0 | 46.40 | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 2.38 | - | - | - | 0.56 | - | 2 | 2 |
| Capex / Sales | 29.51% | - | - | - | 8.97% | - | 5.13% | 2.99% |
| Announcement Date | 2/14/19 | 2/28/20 | 2/26/21 | 2/24/22 | 2/23/23 | 2/23/24 | - | - |
1SEK in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -77.76% | 4.7M | |
| +0.87% | 856M | |
| -28.71% | 225M | |
| -32.85% | 77.72M | |
| +12.44% | 59.81M |
- Stock Market
- Equities
- CLS B Stock
- Financials Clinical Laserthermia Systems AB
